BioCentury on BioBusiness,
Tools & Techniques
Replidyne's C. difficile solution
Monday, September 24, 2007
Replidyne Inc. last week unveiled REP3123, a MetRS inhibitor in preclinical development that the company thinks will be more effective for severe Clostridium difficile-associated diarrhea than vancomycin.
RDYN thinks REP3123 will have two other advantages over vancomycin: it may reduce CDAD relapses because it reduces the bacterium's sporulation and toxin production, and it should have less effect on beneficial gut flora because it has a narrow spectrum of activity against C. difficile, including the BI/NAP1 and VRE strains. BI/NAP1 has increased sporulation over other strains of C. difficile, while VRE is resistant to vancomycin.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]